Clinical Trials Sponsored by Lundbech Foundation

Total 16107 results

H. Lundbeck A/S

Completed

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

Depressive Disorder | Anxiety Disorder

United States, Germany
H. Lundbeck A/S

Terminated

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

Alcohol Dependence

France, Germany, Spain, United Kingdom
H. Lundbeck A/S

Completed

Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder

Major Depressive Disorder
H. Lundbeck A/S

Completed

Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

Schizophrenia

France
H. Lundbeck A/S

Completed

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Major Depressive Disorder

Ukraine, Lithuania, France, Austria, Russian Federation, Australia, Belgium, Canada, Czech Republic, Finland, India, Korea, Republic of, Malaysia, Norway, Philippines, Serbia, Sweden
H. Lundbeck A/S

Completed

Efficacy of Lu 31-130 in Patients With Schizophrenia

Schizophrenia

Germany
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Alzheimer Disease

Germany
H. Lundbeck A/S

Completed

Bioequivalence Study of Idalopirdine Tablets 60 mg

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Heptic Impairment

Germany
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

Schizophrenia

United States
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

Schizophrenia

United States
H. Lundbeck A/S

Completed

MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

Primary Insomnia
H. Lundbeck A/S

Terminated

Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)

Primary Insomnia
H. Lundbeck A/S

Withdrawn

An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)

Insomnia
H. Lundbeck A/S

Completed

Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)

Insomnia
H. Lundbeck A/S

Completed

Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Parkinson's Disease

China
H. Lundbeck A/S

Completed

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Major Depressive Disorder
H. Lundbeck A/S

Completed

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Healthy Men

United Kingdom
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (FOCUS)

Major Depressive Disorder
H. Lundbeck A/S

Terminated

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

Canada
H. Lundbeck A/S

Completed

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

Schizophrenia

China
H. Lundbeck A/S

Completed

Exploratory Cognition Study of Sertindole in Patients With Schizophrenia

Schizophrenia

Taiwan
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women

Parkinson's Disease

China
H. Lundbeck A/S

Completed

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use (SCoP)

Schizophrenia
H. Lundbeck A/S

Completed

Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

France, Netherlands, United Kingdom, Finland, Singapore
H. Lundbeck A/S

Completed

Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

Finland, France, Netherlands, Singapore, United Kingdom
H. Lundbeck A/S

Completed

A Study of Gaboxadol in Primary Insomnia

Primary Insomnia

Sweden
H. Lundbeck A/S

Completed

A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia

Primary Insomnia
H. Lundbeck A/S

Recruiting

A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men

Healthy Participants

United Kingdom
H. Lundbeck A/S

Recruiting

A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants

Healthy Participants

Netherlands
H. Lundbeck A/S

Recruiting

A Study Investigating Lu AG06474 in Healthy Young Participants

Healthy Participants

United States
H. Lundbeck A/S

Completed

A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

Migraine | Migraine in Children

United States
H. Lundbeck A/S

Completed

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE)

Symptomatic Neurogenic Orthostatic Hypotension

United States
H. Lundbeck A/S

Terminated

Real World Effectiveness of Eptinezumab in Participants With Migraine (EVEC)

Migraine

United States
H. Lundbeck A/S

Completed

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Migraine

United States
H. Lundbeck A/S

Terminated

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

Focal Epilepsy

United States
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Healthy Volunteers

Japan
H. Lundbeck A/S

Terminated

A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia

Fibromyalgia

United States
H. Lundbeck A/S

Completed

A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants

Healthy

United Kingdom
H. Lundbeck A/S

Terminated

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Healthy

United States
H. Lundbeck A/S

Completed

Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects

Healthy

China
H. Lundbeck A/S

Completed

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

Healthy

Netherlands
H. Lundbeck A/S

Completed

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

Healthy

United States
H. Lundbeck A/S

Completed

Eptinezumab in Healthy Japanese Subjects

Healthy

Japan
H. Lundbeck A/S

Terminated

Safety and Tolerability of Lu AF95245 in Healthy Young Men

Healthy

Netherlands
H. Lundbeck A/S

Terminated

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Alzheimer Disease

Finland, Sweden
H. Lundbeck A/S

Terminated

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Alzheimer Disease

Austria, Finland, Sweden
H. Lundbeck A/S

Completed

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Bioequivalence Study of Lu AF35700

Healthy

United Kingdom

3

Subscribe